i-SENS, Inc. (099190.KQ)
KRW 15830.0
(-0.19%)
KRW 15830.0
(-0.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 195.32 Billion KRW | 34.88% |
| 2022 | 144.81 Billion KRW | 0.26% |
| 2021 | 144.43 Billion KRW | 72.15% |
| 2020 | 83.9 Billion KRW | 21.69% |
| 2019 | 68.95 Billion KRW | 0.25% |
| 2018 | 68.78 Billion KRW | -0.21% |
| 2017 | 68.92 Billion KRW | 9.69% |
| 2016 | 62.83 Billion KRW | 23.17% |
| 2015 | 51.01 Billion KRW | 14.12% |
| 2014 | 44.7 Billion KRW | 20.5% |
| 2013 | 37.09 Billion KRW | 57.12% |
| 2012 | 23.6 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 239.66 Billion KRW | 22.68% |
| 2024 Q1 | 195.35 Billion KRW | 0.02% |
| 2023 Q4 | 195.32 Billion KRW | 2.85% |
| 2023 Q1 | 148.13 Billion KRW | 2.3% |
| 2023 Q2 | 149.62 Billion KRW | 1.01% |
| 2023 FY | 195.32 Billion KRW | 34.88% |
| 2023 Q3 | 189.9 Billion KRW | 26.92% |
| 2022 FY | 144.81 Billion KRW | 0.26% |
| 2022 Q1 | 151.05 Billion KRW | 4.58% |
| 2022 Q3 | 163.14 Billion KRW | 2.86% |
| 2022 Q4 | 144.81 Billion KRW | -11.23% |
| 2022 Q2 | 158.6 Billion KRW | 5.0% |
| 2021 FY | 144.43 Billion KRW | 72.15% |
| 2021 Q1 | 89.69 Billion KRW | 6.91% |
| 2021 Q2 | 86.31 Billion KRW | -3.78% |
| 2021 Q4 | 144.43 Billion KRW | 63.42% |
| 2021 Q3 | 88.38 Billion KRW | 2.41% |
| 2020 Q1 | 68.79 Billion KRW | -0.23% |
| 2020 Q3 | 81.78 Billion KRW | 27.4% |
| 2020 FY | 83.9 Billion KRW | 21.69% |
| 2020 Q4 | 83.9 Billion KRW | 2.59% |
| 2020 Q2 | 64.19 Billion KRW | -6.68% |
| 2019 Q1 | 70.94 Billion KRW | 3.15% |
| 2019 FY | 68.95 Billion KRW | 0.25% |
| 2019 Q3 | 71.69 Billion KRW | 5.43% |
| 2019 Q2 | 68 Billion KRW | -4.15% |
| 2019 Q4 | 68.95 Billion KRW | -3.83% |
| 2018 Q4 | 68.78 Billion KRW | -5.38% |
| 2018 Q1 | 71.07 Billion KRW | 3.12% |
| 2018 Q2 | 68.87 Billion KRW | -3.09% |
| 2018 FY | 68.78 Billion KRW | -0.21% |
| 2018 Q3 | 72.68 Billion KRW | 5.53% |
| 2017 Q4 | 68.92 Billion KRW | -6.6% |
| 2017 Q3 | 73.79 Billion KRW | 2.52% |
| 2017 Q1 | 58.29 Billion KRW | -7.22% |
| 2017 FY | 68.92 Billion KRW | 9.69% |
| 2017 Q2 | 71.98 Billion KRW | 23.47% |
| 2016 Q3 | 50.16 Billion KRW | -7.49% |
| 2016 FY | 62.83 Billion KRW | 23.17% |
| 2016 Q4 | 62.83 Billion KRW | 25.25% |
| 2016 Q2 | 54.22 Billion KRW | 9.24% |
| 2016 Q1 | 49.64 Billion KRW | 4.33% |
| 2015 Q2 | 45.24 Billion KRW | 1.7% |
| 2015 FY | 51.01 Billion KRW | 14.12% |
| 2015 Q1 | 44.48 Billion KRW | -0.49% |
| 2015 Q4 | 47.57 Billion KRW | 10.49% |
| 2015 Q3 | 43.06 Billion KRW | -4.82% |
| 2014 Q3 | 34.64 Billion KRW | -0.82% |
| 2014 FY | 44.7 Billion KRW | 20.5% |
| 2014 Q2 | 34.93 Billion KRW | -3.44% |
| 2014 Q4 | 44.7 Billion KRW | 29.02% |
| 2014 Q1 | 36.17 Billion KRW | -2.47% |
| 2013 Q1 | 21.4 Billion KRW | -9.32% |
| 2013 Q3 | 21.3 Billion KRW | 7.16% |
| 2013 Q4 | 37.09 Billion KRW | 74.11% |
| 2013 Q2 | 19.88 Billion KRW | -7.13% |
| 2013 FY | 37.09 Billion KRW | 57.12% |
| 2012 FY | 23.6 Billion KRW | 0.0% |
| 2012 Q4 | 23.6 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 27.25 Billion KRW | -616.617% |
| InBody Co.,Ltd | 24.62 Billion KRW | -693.304% |
| Curexo Inc. | 6.94 Billion KRW | -2714.002% |
| Seegene, Inc. | 221.05 Billion KRW | 11.64% |
| Ray Co., Ltd. | 128.35 Billion KRW | -52.171% |
| Gencurix Inc. | 21.49 Billion KRW | -808.53% |
| Sugentech Inc. | 20.73 Billion KRW | -842.117% |
| L&C Bio Co., Ltd | 105.37 Billion KRW | -85.359% |